​

Estrella Immunopharma Stock (NASDAQ:ESLA)

FinancialsChart
Estrella Immunopharma by TradingView

Previous Close

$2.38

52W Range

$0.63 - $2.55

50D Avg

$1.29

200D Avg

$1.07

Market Cap

$84.51M

Avg Vol (3M)

$135.64K

Beta

0.39

Div Yield

-

ESLA Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Sep 14, 2021

Website

ESLA Performance

ESLA Financial Summary

Jun 24Dec 22Jun 22
Revenue---
Operating Income$-7.31M$-1.57M$-1.69M
Net Income$-7.31M$-996.10K$-1.69M
EBITDA$-7.31M$-1.57M$-1.69M
Basic EPS$-0.27$-0.17$-0.29
Diluted EPS$-0.27$-0.17$-0.29

Fiscal year ends in Jun 24 | Currency in USD

Peer Comparison

TickerCompany
OSTXOS Therapies Incorporated
CUECue Biopharma, Inc.
OTLKOutlook Therapeutics, Inc.
BYSIBeyondSpring Inc.
INKTMiNK Therapeutics, Inc.
MNOVMediciNova, Inc.
VERUVeru Inc.
GNTAGenenta Science S.p.A.
VTVTvTv Therapeutics Inc.
RLMDRelmada Therapeutics, Inc.